alzheimer’s, biotechnology, cardiovascular disease, clinical trials, diabetes, drug development, drug prices, eli lilly, fda, hhs, jpm, novo nordisk, obesity, pfizer, pharmaceuticals, policy, reporters, research, rfk jr., stat+, weight loss, donald trump, diversity and inclusion